Systemic corticosteroid therapy augments ex vivo release
of sCD163 by peripheral blood monocytes of asthmatic
patients

Paweł Bernatowicz; Paweł Golec; Paweł Bielecki; Krzysztof Kowal

doi:10.5114/ada.2020.93384

eISSN: 2299-0046
ISSN: 1642-395X

Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii

Current issue Archive Manuscripts accepted About the journal Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

1/2020
vol. 37

Send email

Copy url:

abstract:

Original paper

Systemic corticosteroid therapy augments ex vivo release of sCD163 by peripheral blood monocytes of asthmatic patients

Paweł L. Bernatowicz

¹

,

Paweł Golec

²

,

Paweł Bielecki

³

,

Krzysztof Kowal

^{4, 5}

Department of Haematology, Medical University of Bialystok, Bialystok, Poland
Department of Thoracic Surgery, Medical University of Bialystok, Bialystok, Poland
Department of Otolaryngology, Medical University of Bialystok, Bialystok, Poland
Department of Experimental Allergology and Immunology, Medical University of Bialystok, Bialystok, Poland
Department of Allergology and Internal Medicine, Medical University of Bialystok, Bialystok, Poland

Adv Dermatol Allergol 2020; XXXVII (1): 61-65

DOI: https://doi.org/10.5114/ada.2020.93384

Online publish date: 2020/03/09

View full text Get citation

EndNote

Papers, Reference Manager, RefWorks, Zotero

AMA

Bernatowicz PL, Golec P, Bielecki P, Kowal K. Systemic corticosteroid therapy augments ex vivo release
of sCD163 by peripheral blood monocytes of asthmatic
patients. Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii. 2020;37(1):61-65. doi:10.5114/ada.2020.93384.

APA

Bernatowicz, P. L., Golec, P., Bielecki, P.,  & Kowal, K. (2020). Systemic corticosteroid therapy augments ex vivo release
of sCD163 by peripheral blood monocytes of asthmatic
patients. Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii, 37(1), 61-65. https://doi.org/10.5114/ada.2020.93384

Chicago

Bernatowicz, Paweł L, Paweł Golec, Paweł Bielecki,  and Krzysztof Kowal. 2020. "Systemic corticosteroid therapy augments ex vivo release
of sCD163 by peripheral blood monocytes of asthmatic
patients". Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii 37 (1): 61-65. doi:10.5114/ada.2020.93384.

Harvard

Bernatowicz, P., Golec, P., Bielecki, P.,  and Kowal, K. (2020). Systemic corticosteroid therapy augments ex vivo release
of sCD163 by peripheral blood monocytes of asthmatic
patients. Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii, 37(1), pp.61-65. https://doi.org/10.5114/ada.2020.93384

MLA

Bernatowicz, Paweł et al. "Systemic corticosteroid therapy augments ex vivo release
of sCD163 by peripheral blood monocytes of asthmatic
patients." Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii, vol. 37, no. 1, 2020, pp. 61-65. doi:10.5114/ada.2020.93384.

Vancouver

Bernatowicz P, Golec P, Bielecki P, Kowal K. Systemic corticosteroid therapy augments ex vivo release
of sCD163 by peripheral blood monocytes of asthmatic
patients. Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii. 2020;37(1):61-65. doi:10.5114/ada.2020.93384.

Introduction
The CD163 is exclusively expressed by mononuclear phagocytes as a transmembrane protein, which synthesis is regulated by anti- and pro-inflammatory signals. After shedding from the cell surface it exists in body fluids as a soluble protein (sCD163) which exerts anti-inflammatory effects.

Aim
To evaluate serum concentration and ex vivo production of sCD163 by peripheral blood mononuclear cells (PBMC) in asthmatic patients treated with inhaled (ICS) or oral corticosteroids (OCS).

Material and methods
The study was performed on 35 allergic asthma patients (AAs) including 15 treated with ICS (ICS-AAs), 10 with OCS (OCS-AAs), 10 during asthma exacerbation (EX-AAs) before OCS had been started and 13 non-atopic healthy subjects (HCs) as a control group. PBMC were cultured in vitro for up to 144 h. The concentration of sCD163 in serum and the culture supernatants was evaluated with ELISA.

Results
The greatest serum sCD163 concentration was demonstrated in EX-AAs, which was significantly greater than that in other studied subgroups. The concentration of sCD163 in PBMC culture supernatants was greater in AAs than in HCs (p = 0.006). Among individual asthma subgroups the greatest concentration of sCD163 was demonstrated in PBMC culture supernatants of OCS-AAs, which was significantly greater than in ICS-AAs (p < 0.001) and EX-AAs (p < 0.001), both being significantly greater than in HCs (p < 0.001).

Conclusions
In AAs, enhanced capability of PBMCs to release sCD163 may be at least partially responsible for the anti-inflammatory effects of systemic corticosteroid therapy.

keywords:

Systemic corticosteroid therapy augments ex vivo release of sCD163 by peripheral blood monocytes of asthmatic patients

Paweł L. Bernatowicz 1 , Paweł Golec 2 , Paweł Bielecki 3 , Krzysztof Kowal 4, 5

CD163, asthma, inhaled corticosteroids, induced sputum

Paweł L. Bernatowicz

¹

,

Paweł Golec

²

,

Paweł Bielecki

³

,

Krzysztof Kowal

^{4, 5}